Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Review ArticleContinuing Education

Statistical Considerations in the Evaluation of Continuous Biomarkers

Mei-Yin C. Polley and James J. Dignam
Journal of Nuclear Medicine May 2021, 62 (5) 605-611; DOI: https://doi.org/10.2967/jnumed.120.251520
Mei-Yin C. Polley
Department of Public Health Sciences, University of Chicago, Chicago, Illinois, and NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James J. Dignam
Department of Public Health Sciences, University of Chicago, Chicago, Illinois, and NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Hypothetical relationship between biomarker M and clinical outcome. (A) Green line depicts linear relationship between biomarker and outcome. Risk of outcome increases linearly with increasing biomarker values. Dashed lines illustrate effect of dichotomizing biomarker, assuming that discontinuity in risk occurs at cut point c (patients whose biomarker values are below cut point are conferred the same risk, which is lower by magnitude Δ than that conferred to patients whose biomarker values exceed cut point). c* represents the biomarker value of a patient whose true risk is highest in the high-risk subgroup. (B) Quadratic relationship between biomarker and outcome. Risk of outcome decreases with biomarker up to point m and increases linearly after m.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Dichotomy of continuous biomarker (NLR example). (A) Nonlinear relationship between NLR and patient survival in Mayo Clinic triple-negative breast cancer dataset using restricted spline method. (B) Effect of dichotomizing NLR at its sample median. Association between NLR and survival is no longer significant (log-rank P = 0.27). AIC = Akaike’s information criterion; L.R. = likelihood ratio.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Minimal-P-value approach (NLR example). (A) Highly unstable P values of log-rank test as function of cut point used for NLR in Mayo Clinic triple-negative breast cancer dataset. Top and bottom 20% of NLR values were excluded, and 200 cut points were used. (B) Strong inverse correlation between estimated HRs and log-rank P values for NLR in Mayo Clinic triple-negative breast cancer dataset. Smallest P value corresponds to most extreme HR estimate.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Type I error inflation as function of number of cut points and sample size using minimal-P-value approach. In each simulation, 10% of smallest and largest biomarker values were not considered as potential cut points. Two-sided P value from log-rank test was computed for each cut point applied. Each plotted point represents percentage of 5,000 simulations for which minimal P value is less than nominal 5% level based on assumption that there is no association between biomarker and time-to-event outcome (i.e., type I error). No censoring in outcome was assumed.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Effect of number of covariates (k) in risk model on resubstitution bias in AUC. Population box plot represents true AUC distribution in interested population at large. Sample box plot represents distribution of AUC derived from sample dataset used to construct risk model. Each box plot was based on 1,000 simulations. When k = 5, there is slight upward (optimistic) bias in sample AUC distribution compared with true population. Degree of optimistic bias increases drastically when k increases to 50.

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    Schema for biomarker cut point analysis and evaluation.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (5)
Journal of Nuclear Medicine
Vol. 62, Issue 5
May 10, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Statistical Considerations in the Evaluation of Continuous Biomarkers
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Statistical Considerations in the Evaluation of Continuous Biomarkers
Mei-Yin C. Polley, James J. Dignam
Journal of Nuclear Medicine May 2021, 62 (5) 605-611; DOI: 10.2967/jnumed.120.251520

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Statistical Considerations in the Evaluation of Continuous Biomarkers
Mei-Yin C. Polley, James J. Dignam
Journal of Nuclear Medicine May 2021, 62 (5) 605-611; DOI: 10.2967/jnumed.120.251520
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • STATISTICAL PITFALLS IN BIOMARKER CUT POINT SEARCH AND ANALYSIS
    • BIOMARKER CUT POINT IN THE PRESENCE OF ESTABLISHED PROGNOSTIC FACTORS
    • CONCLUSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Similar performance of 8 machine learning models on 71 censored medical datasets: a case for simplicity
  • Circulating biomarkers of kidney tumors in TSC (tuberous sclerosis complex) patients
  • Cut Point Identification of Continuous Biomarkers: A Challenge That Goes Beyond Statistical Aspects
  • Google Scholar

More in this TOC Section

  • Approaches to Imaging Immune Activation Using PET
  • Large Language Models and Large Multimodal Models in Medical Imaging: A Primer for Physicians
  • Precision Oncology in Melanoma: Changing Practices
Show more Continuing Education

Similar Articles

Keywords

  • statistics
  • area under the ROC curve
  • biomarker cut point
  • biomarker discretization
  • prognostic biomarker
  • resubstitution statistics
SNMMI

© 2025 SNMMI

Powered by HighWire